Bristol Myers Squibb’s Heart Medication Camzyos Receives NICE Recommendation

Bristol Myers Squibb (BMS) has received a recommendation for approval from the UK’s National Institute for Health and Care Excellence (NICE) for its heart drug Camzyos (mavacamten). The recommendation covers the use of the drug as a adjunct treatment for symtompatic obstructive hypertrophic cardiomyopathy, a condition of reduced blood flow caused by thickening of certain walls in the heart.

According to Paul Schlosser, “NICE recommended the drug for several reasons. While the standard care for the disease treats symptoms, the organization said Camzyos is the first to treat oHCM, as compared with beta blockers, certain calcium channel blockers or disopyramide. Some of those treatments have side effects and are not always effective, the organization said.”

To read more, click here.

(Source: Endpoints News, June 2^nd, 2023)